Andrew M Busch1,2, Dawn M Nederhoff3, Shira I Dunsiger4, Sandra J Japuntich5,6, Michelle Chrastek7, Melissa Adkins-Hempel7, Linda M Rinehart8, Harry Lando3. 1. Department of Medicine, Hennepin Healthcare, 701 Park Avenue, S9-309, Minneapolis, MN, 55415, USA. andrew.busch@hcmed.org. 2. Department of Medicine, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. andrew.busch@hcmed.org. 3. Division of Epidemiology and Community Health, University of Minnesota, 1300 South 2nd Street, Minneapolis, MN, 55454, USA. 4. Department of Behavioral and Social Sciences, Center for Health Promotion and Health Equity, Brown University, School of Public Health, Box G-S121-8, Providence, RI, 02912, USA. 5. Department of Medicine, Hennepin Healthcare, 701 Park Avenue, S9-309, Minneapolis, MN, 55415, USA. 6. Department of Medicine, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. 7. Hennepin Healthcare Research Institute, 701 Park Avenue, PP7.700, Minneapolis, MN, 55415, USA. 8. Department of Psychiatry & Behavioral Sciences, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA.
Abstract
BACKGROUND: Rates of smoking among those with serious mental illness (SMI) are two to three times higher than for the general population. Smoking is rarely addressed in mental health settings. Innovative outreach and treatment strategies are needed to address these disparities. The current study is a pilot study of the feasibility and acceptability of a chronic care model of tobacco cessation treatment implemented in outpatient psychiatry clinics. METHODS:Participants were recruited from two outpatient psychiatric clinics and randomly assigned to intervention (counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment) or control (brief education and referral to the state quit line). Assessments were conducted at 8 weeks (end of initial treatment block) and 6 months (end of window for retreatment). Feasibility was assessed by enrollment rate, treatment engagement, and completion of follow-up assessments. Acceptability was assessed both quantitatively and qualitatively. Preliminary efficacy was assessed by 7-day and 30-day abstinence rates, rate of quit attempts, and cigarettes per day. Psychological health was measured to assess for changes related to treatment group or attempts to quit smoking. RESULTS:Nineteen participants were randomized to intervention and 19 to control. Recruitment proved feasible, and high rates of treatment engagement (mean of 4.5 sessions completed in initial treatment block, 89.5% uptake of nicotine replacement) and retention (94.7% of follow-up assessments completed) were observed. Treatment acceptability was high. As anticipated, there were no significant differences in abstinence between groups, but results generally favored the intervention group, including bio-verified 7-day abstinence rates of 21.1% in intervention vs. 17.6% in control and self-reported 30-day abstinence rates of 16.1% in intervention vs. 5.1% in control at 8 weeks. Significantly more intervention participants made at least one quit attempt (94.7% vs 52.6%; OR = 16.20, 95% CI: 1.79-147.01). Cigarettes per day decreased significantly more in the intervention group at 8 weeks (b = - 13.19, SE = 4.88, p = .02). CONCLUSIONS: It was feasible to recruit and retain SMI patients in a smoking cessation trial in the context of outpatient psychiatry. The novel chronic care model treatment was acceptable to patients and showed promise for efficacy. If efficacious, a chronic care model could be effective at reducing smoking among SMI patients. TRIAL REGISTRATION: ClinicalTrial.gov #: NCT03822416 (registered January 30th 2019).
RCT Entities:
BACKGROUND: Rates of smoking among those with serious mental illness (SMI) are two to three times higher than for the general population. Smoking is rarely addressed in mental health settings. Innovative outreach and treatment strategies are needed to address these disparities. The current study is a pilot study of the feasibility and acceptability of a chronic care model of tobacco cessation treatment implemented in outpatient psychiatry clinics. METHODS:Participants were recruited from two outpatientpsychiatric clinics and randomly assigned to intervention (counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment) or control (brief education and referral to the state quit line). Assessments were conducted at 8 weeks (end of initial treatment block) and 6 months (end of window for retreatment). Feasibility was assessed by enrollment rate, treatment engagement, and completion of follow-up assessments. Acceptability was assessed both quantitatively and qualitatively. Preliminary efficacy was assessed by 7-day and 30-day abstinence rates, rate of quit attempts, and cigarettes per day. Psychological health was measured to assess for changes related to treatment group or attempts to quit smoking. RESULTS: Nineteen participants were randomized to intervention and 19 to control. Recruitment proved feasible, and high rates of treatment engagement (mean of 4.5 sessions completed in initial treatment block, 89.5% uptake of nicotine replacement) and retention (94.7% of follow-up assessments completed) were observed. Treatment acceptability was high. As anticipated, there were no significant differences in abstinence between groups, but results generally favored the intervention group, including bio-verified 7-day abstinence rates of 21.1% in intervention vs. 17.6% in control and self-reported 30-day abstinence rates of 16.1% in intervention vs. 5.1% in control at 8 weeks. Significantly more intervention participants made at least one quit attempt (94.7% vs 52.6%; OR = 16.20, 95% CI: 1.79-147.01). Cigarettes per day decreased significantly more in the intervention group at 8 weeks (b = - 13.19, SE = 4.88, p = .02). CONCLUSIONS: It was feasible to recruit and retain SMI patients in a smoking cessation trial in the context of outpatient psychiatry. The novel chronic care model treatment was acceptable to patients and showed promise for efficacy. If efficacious, a chronic care model could be effective at reducing smoking among SMI patients. TRIAL REGISTRATION: ClinicalTrial.gov #: NCT03822416 (registered January 30th 2019).
Authors: Anne M Joseph; Steven S Fu; Bruce Lindgren; Alexander J Rothman; Molly Kodl; Harry Lando; Brandon Doyle; Dorothy Hatsukami Journal: Arch Intern Med Date: 2011-11-28
Authors: Erin S Rogers; Steven S Fu; Paul Krebs; Siamak Noorbaloochi; Sean M Nugent; Amy Gravely; Scott E Sherman Journal: Am J Prev Med Date: 2018-03-15 Impact factor: 5.043
Authors: Sandra J Japuntich; Patrick J Hammett; Erin S Rogers; Steven Fu; Diana J Burgess; Omar El Shahawy; Anne C Melzer; Siamak Noorbaloochi; Paul Krebs; Scott E Sherman Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Alexandra P Metse; John Wiggers; Paula Wye; Richard Clancy; Lyndell Moore; Maree Adams; Maryanne Robinson; Jenny A Bowman Journal: J Behav Med Date: 2016-06-29
Authors: Steven S Fu; Michelle van Ryn; David Nelson; Diana J Burgess; Janet L Thomas; Jessie Saul; Barbara Clothier; John A Nyman; Patrick Hammett; Anne M Joseph Journal: Thorax Date: 2016-03-01 Impact factor: 9.139
Authors: Nicole Moschny; Gudrun Hefner; Renate Grohmann; Gabriel Eckermann; Hannah B Maier; Johanna Seifert; Johannes Heck; Flverly Francis; Stefan Bleich; Sermin Toto; Catharina Meissner Journal: Pharmaceuticals (Basel) Date: 2021-05-27